// App-Quantinova.ai

BSH19‐PO‐085 : Long‐term ibrutinib therapy reverses CD8 + T cell exhaustion in B cell chronic lymphocytic leukaemia

Researchers

Presenter

  • H. Parry

Principal Investigators

  • N. Mirajkar

  • N. Cutmore

  • J. Zuo

  • H. Long

  • M. Kwok

  • C. Oldrieve

  • C. Hudson

  • S. Paneesha

  • M. Kelly

  • J. Begum

  • T. McSkeane

  • G. Pratt

  • P. Moss

Medical Centers

  • Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom

  • Radiology, University Hospital Birmingham, Birmingham

  • Pathology, St James’ University Hospital, Leeds

  • Immunology and Immunotherapy

  • Institute of Cancer and Genomic studies, University of Birmingham, Birmingham

  • Faculty of Medicine and Health Sciences, University of Nottingham, Leicestershire

  • Haematology, Heartlands Hospital

  • Cancer Research UK Clinical Trials Unit, Birmingham, University of, Birmingham

  • Haematology, Universtiy of Birmingham, Birmingham, United Kingdom,

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • Cluster of Differentiation 2AP

  • Cluster of differentiation 8A

Drug/Treatment

  • Ibrutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved